Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hypertension
Volume 2013 (2013), Article ID 541689, 9 pages
Clinical Study

Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study

1Clinical Cardiology Institute A.L. Myasnikov FSI Russian Cardiology Scientific and Production Complex Ministry of Health, 3rd Cherepkovskaya No. 15, Moscow 121552, Russia
2Neurovascular Hypertension and Kidney Disease Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, VIC 8008, Australia

Received 19 November 2012; Accepted 12 January 2013

Academic Editor: Eduardo Vera Tibiriçá

Copyright © 2013 Irina Chazova and Markus P. Schlaich. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


This study was designed to assess the effects of moxonidine on blood pressure and aspects of the metabolic syndrome in racially diverse population of patients encountered in routine medical practice. Physicians collected data on a minimum of three consecutive patients with uncontrolled essential hypertension and criteria for metabolic syndrome, eligible to receive moxonidine (0.2–0.4 mg once daily) for 6 months, either as monotherapy or as adjunct therapy to current antihypertensive treatment. Systolic and diastolic blood pressure (BP) declined by an average of  mmHg and  mmHg, respectively. BP responder rates defined as attaining BP < 140/90 mmHg were significantly ( ) and substantially higher among younger patients, nonpostmenopausal women, and patients receiving monotherapy. While potentially relevant improvements in the entire cohort were observed in regard to body weight (  kg), fasting plasma glucose (from 6.8 to 6.2 mmol/L), and triglycerides (2.4 to 2.0 mmol/L), statistically significant changes in metabolic parameters could only be detected in subgroup analyses. Moxonidine therapy reduced blood pressure and improved rates of blood pressure control in this group of patients. While the observed trend towards improvement in various metabolic parameters merits further investigation, the overall effect of moxonidine treatment is consistent with a reduction of total cardiovascular risk in this hypertensive metabolic syndrome cohort.